Table 5 Patient selection criteria along with the resulting tumor profiles in each of the studies and the mean total lymph node harvests.

Tis

T1

T2

T3

T4

Saha

None

ns

Data not given

ns

37

16 (ns)

Wiese

None

ns

0

14

22

53

11

36:63

41

16 (ns)

Waters

None

ns

Data not given

ns

27

12 (ns)

Bilchik

Early stage primary only

ns

0

26

24

50

50:50

35

15 (2–28)

Paramo

No distant metastatic disease

ns

0

12

7

81

0

7:93

29

10 (ns)

Wood

Clinically localized primary

ns

0

19

29

44

8

48:52

47

15 (2–28)

Wood

Small early stage cancers only

1.4

27

54

9

9

0

91:9

9

13 (2–20)

Saha

None

ns

Data not given

ns

40

20 (ns)

Esser

No nodal or distant metastases

ns

Data not given

ns

19.4

15 (12–16)

Bendavid

None

ns

Data not given

ns

65

ns

Paramo

No distant metastatic disease

ns

Data not given

ns

27

12 (ns)

Wood

Clinically localized

ns

Data not given

ns

26

15 (2–28)

Bilchik

Clinically localized

ns

0

25

23

46

6

48:52

43

15 (3–28)

Kitagawa

Only if curative surgery

ns

Data not given

29:71

43

24 (ns)

Feig

None

ns

7

6

23

58

6

36:64

33

13 (4–46)

Broderick-Villa

No known distant metastases

?

6

8

20

62

4

34:66

43

8 (1–17)

Tsioulias

Clinically localized only

ns

Data not given

ns

21

14 (2–21)

Nastro

None

ns

Data not given

ns

ns

ns

Bilchik

Early stage primary only

ns

20

46

14

20

0

80:20

21

14 (2–21)

Cox

None

ns

0

6

36

58

0

42:58

41

18 (4–33)

Bilchik

Early stage primary only

3.6

14

12

17

53

5

42:58

36

14 (ns)

Turner

None

ns

0

12

10

75

4

22:78

52

11 (1–42)

Trocha

No distant metastases

ns

26

12

18

42

2

56:44

38

16 (ns)

Veihl

None

4.2

0

6

9

71

12

15:83

48

21 (5–40)

Levine

No gross nodal disease

ns

Data not given

ns

ns

ns

Saha

Tumor resectable & no metastases

ns

Data not given

ns

42

ns

Dan

None

ns

17

15

13

53

3

ns

43

ns

Braat

No distant metastases, gross invasion or nodal disease

ns

0

6

20

51

23

26:74

34

9 (1–23)

Bertoglio

Stage I and II & no enlarged nodes only

ns

Data not given

ns

65

13 (6–18)

Read

Surgery with curative intent only

ns

Data not given

ns

29

14 (7–45)

Patten

No nodal or distant metastases

ns

Data not given

37:63

39

14 (ns)

Bertagnolli

Stage I, II and III only

ns

0

29

16

46

9

35:65

67

17 (ns)

Saha

None

ns

19

14

11

53

4

43:57

33

12 (ns)

Saha

None

ns

11

10

15

51

5

34:66

41

14 (ns)

Bembenek

Conventionally node negative patients only

ns

Data not given

ns

100

26 (10–59)

Codnignola

No liver metastases

ns

0

2

21

63

14

23:77

36

21 (6–47)

Dahl

No nodal or distant metastases

ns

Data not given

11:88

40

17 (4–35)

Bilchik

Potentially curable cancer with no distant metastases only

3.5 (0.2–10.5)

0

17

15

65

3

32:68

29

15 (ns)

Tuech

No nodal or distant disease

ns

0

6

9

85

0

10:90

36

20 (12–32)

Saha

None

ns

15

11

16

52

5

42:58

50

15 (ns)

Kelder

No gross nodal or distant metastases

ns

0

0

23

73

4

23:77

21

14 (ns)

Thomas

None

ns

Data not given

?

38

ns

Covarelli

None

ns

Data not given

ns

35

ns

Kelder

No gross nodal or distant metastases

ns

0

1

20

70

9

21:79

41

11 (ns)

Bianchi

No T4 or metastatic disease

ns

36

4.5

9

45

5

50:50

73

22 (8–38)

Murawa

No gross nodal or distant metastases

ns

0

15

20

63

2

37:63

41

20 (3–96)

Bembenek

None

ns

Data not given

ns

69

20 (4–79)

Sandrucci

Stage I or II only

ns

Data not given

100:0

69

9 (ns)

Tiffet

Excluded if primary unresectable.

ns

Data not given

22:78

41

18 (4–37)

Lim

No gross nodal or distant metastases

ns

0

4

26

66

4

30:70

16

13(ns)

Kusano

None

ns

0

15

73

12

88:12

77

13.5 (ns)

Quadros

Potential curable cancer, no distant metastases

8.3

0

0

14

54

31

14:86

46

19 (ns)